

APPENDIX V

STATUTORY AND GENERAL INFORMATION

A. FURTHER INFORMATION ABOUT OUR GROUP

1. Establishment of Our Company

Our Company was established as a limited liability company in the PRC on March 11, 1999 and was converted into a joint stock limited company on November 27, 2020. Our registered office is located at No. 35 Jingxin Road, Industrial Park, Xibei Town, Xishan District, Wuxi, Jiangsu Province, PRC. Our Company has established a place of business in Hong Kong, at 40th Floor, Dah Sing Financial Center, No. 248 Queen’s Road East, Wanchai, and has been registered as a non-Hong Kong company under Part 16 of the Companies Ordinance on July 2, 2026. Ms. Au Wing Han (區泳嫻) has been appointed as our authorized representative for acceptance of service of process and notices in Hong Kong whose correspondence address is the same as our place of business in Hong Kong.

As our Company is established in the PRC, our corporate structure and Articles of Association are subject to the relevant laws and regulations of the PRC. A summary of the relevant provisions of our Articles of Association is set out in “Appendix IV — Summary of Articles of Association.”

2. Changes in the Share Capital of Our Company

Save as disclosed below and in “History, Development and Corporate Structure,” there has been no change in the share capital of our Company within the two years immediately preceding the date of this document.

Pursuant to the 2024 Outstanding Contribution Incentive Plan as approved at the 2024 second extraordinary Shareholders’ general meeting dated December 5, 2024, the Company repurchased a total of 2,240,000 Shares from Wuxi Jinrunyang at the price of RMB8.50 per Share. Further, as approved at the 2025 first extraordinary Shareholders’ general meeting dated January 27, 2025, the Company completed the cancelation of 1,160,000 Shares repurchased from Wuxi Jinrunyang, which had not been granted under the 2024 Outstanding Contribution Incentive Plan on April 1, 2025. As a result, the total share capital of the Company decreased from RMB129,900,000.00 comprising 129,900,000 Shares to RMB128,740,000.00 comprising 128,740,000 Shares.

Pursuant to the 2025 Share Incentive Plan as approved at the 2025 seventh extraordinary Shareholders’ general meeting dated November 25, 2025, the Company completed the grant of an aggregate of 9,600,308 Shares to ten incentive participants by way of issuance of new Shares and transfer of repurchased Shares at a grant price of RMB1.00 per Share on the same date. Among such Shares, 6,907,108 Shares were newly issued by the Company to the incentive participants. As a result, the total share capital of the Company increased from RMB131,260,892.00 comprising 131,260,892 Shares to RMB138,168,000.00 comprising 138,168,000 Shares.

3. Change in the Share Capital of Our Subsidiaries

A summary of the corporate information and the particulars of our subsidiaries are set out in the Accountants’ Report.

Save as disclosed below, there has been no change in the share capital of our subsidiaries within the two years preceding the date of this document.

Langrun Tech

On September 8, 2025, Langrun Tech was deregistered under the laws of the PRC on a voluntary basis due to cessation of its business with a registered share capital of RMB20,418,668.

APPENDIX V

STATUTORY AND GENERAL INFORMATION

Wuxi Zhiming Pharmaceutical Technology Co., Ltd. (無錫知明醫藥科技有限公司)

On December 24, 2025, Wuxi Zhiming Pharmaceutical Technology Co., Ltd. was deregistered under the laws of the PRC on a voluntary basis due to cessation of its business with a registered share capital of RMB20,000,000.

Wuxi Beirun Enterprise Management Co., Ltd. (無錫倍潤企業管理有限公司)

On December 25, 2025, Wuxi Beirun Enterprise Management Co., Ltd. was deregistered under the laws of the PRC on a voluntary basis due to cessation of its business with a registered share capital of RMB5,000,000.

Zhiyan Bio Korea Co., Ltd.

On January 8, 2025, the registered share capital of Zhiyan Bio Korea Co., Ltd. was increased from KRW900,000,000 to KRW1,240,000,000. On January 5, 2026, the registered share capital of Zhiyan Bio Korea Co., Ltd was increased from KRW1,240,000,000 to KRW1,910,000,000.

Chongqing Zhifu Pharmacy Co., Ltd. (重慶知芙大藥房有限公司)

On March 20, 2026, Chongqing Zhifu Pharmacy Co., Ltd. was established under the laws of the PRC with a registered share capital of RMB5,000,000.

4. Resolutions of Our Shareholders

Pursuant to the resolutions passed at a duly convened extraordinary general meeting of our Shareholders held on June 16, 2026, our Shareholders resolved that, among other things, that:

- (a) the issuance of H Shares with a nominal value of RMB1.00 each and such H Shares being [REDACTED] on the Stock Exchange;
- (b) the number of H Shares to be issued pursuant to the [REDACTED], and the grant to the [REDACTED] (or its representatives) of the [REDACTED] of not more than 15% of the number of H Shares initially available under the [REDACTED];
- (c) subject to the filing procedure with the CSRC, upon the completion of the [REDACTED], [REDACTED] Unlisted Shares held by existing Shareholders will be converted into H Shares on a one-for-one basis;
- (d) subject to the completion of the [REDACTED], the grant of a general mandate to our Board to allot and issue new Shares or sell and/or transfer treasury Shares at any time within a period up to the date of the conclusion of the next annual general meeting of the Shareholders or the date on which the Shareholders pass a special resolution to revoke or change such mandate, whichever is earlier, upon such terms and conditions and for such purposes and to such persons as our Board in their absolute discretion deems fit, and to make necessary amendments to the Articles of Association, provided that the number of Shares to be issued shall not exceed 20% of the number of the H Shares in issue (without taking into account any H Shares that may be issued upon the exercise of the [REDACTED] and treasury Shares, if any) as of the [REDACTED];
- (e) subject to the completion of the [REDACTED], the grant of a general mandate to our Board to repurchase H Shares issued on the Stock Exchange at any time within a period up to the date of the conclusion of the next annual general meeting of our Shareholders or the date on which our Shareholders pass a special resolution to revoke or change such mandate, whichever is earlier, and to complete all necessary procedures, provided that, the number of H Shares to be repurchased shall not exceed 10% of the number of the total H Shares in issue as of the [REDACTED] (without taking into account any H Shares that may be issued upon the exercise of the [REDACTED] and treasury Shares, if any);
- (f) subject to the completion of the [REDACTED], the adoption of the Articles of Association which shall become effective on the [REDACTED], and authorization to our Board to amend the Articles of Association to the extent necessary for the purpose of the [REDACTED]; and
- (g) authorization of our Board or its authorized individual(s) to deal with all matters relating to the [REDACTED] and the [REDACTED].

APPENDIX V

STATUTORY AND GENERAL INFORMATION

5. Restriction on Share Repurchase

For details of the restrictions on share repurchase by our Company, see “Appendix IV — Summary of Articles of Association.”

B. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of Material Contract




We [have] entered into the following contract (not being contract entered into in the ordinary course of business) within the two years immediately preceding the date of this document that is or may be material:

(a) the [REDACTED].

2. Intellectual Property Rights

Trademarks

As of the Latest Practicable Date, we had registered the following trademarks which we considered to be material to our business.

No.	Trademark	Registration number	Owner	Place of registration	Class	Expiry date
1. . . .		307145857	The Company	Hong Kong	3, 5, 10, 35, 44	December 29, 2035
2. . . .		1472605	The Company	PRC	5	November 13, 2030
3. . . .		1472606	The Company	PRC	5	November 13, 2030
4. . . .		3554642	The Company	PRC	5	April 20, 2035
5. . . .		14206451	The Company	PRC	5	April 27, 2035
6. . . .		59748964	The Company	PRC	3	March 27, 2032
7. . . .		59771836	The Company	PRC	5	March 27, 2032
8. . . .		76887294	The Company	PRC	3	July 27, 2034
9. . . .		55141485	The Company	PRC	3	May 20, 2032
10. . .		10073467	The Company	PRC	5	January 6, 2033
11. . .		11962867	The Company	PRC	5	June 13, 2034
12. . .		12613762	The Company	PRC	5	March 20, 2035
13. . .		22281992	Wuxi Zhiyan Biotechnology Co., Ltd. (無錫知妍生物科技有限公司) (“Zhiyan Biotechnology”)	PRC	3	January 27, 2028
14. . .		69370664	Zhiyan Biotechnology	PRC	3	September 6, 2033
15. . .		67651351	Zhiyan Biotechnology	PRC	3	April 13, 2033
16. . .		1343330	Chongqing Yaoyanyuan	PRC	5	December 13, 2029

APPENDIX V

STATUTORY AND GENERAL INFORMATION

Patents

As of the Latest Practicable Date, we had registered the following patents which we considered to be material to our business.

No.	Owner	Patent name	Expiry date	Category	Place of registration
1. . . .	The Company	A method for transdermal detection of azelaic acid (一種用於壬二酸透皮檢測的方法)	March 22, 2043	Invention	PRC
2. . . .	The Company	A method for detecting the content of impurity XV in tacrolimus ointment using reversed-phase chromatography (一種用反相色譜法檢測他克莫司軟膏中雜質XV含量的方法)	December 28, 2041	Invention	PRC
3. . . .	The Company	A tacrolimus ointment and preparation method thereof	January 3, 2043	Invention	PRC
4. . . .	The Company	A cream for dermatitis and its manufacturing process and manufacturing equipment	July 5, 2043	Invention	PRC
5. . . .	The Company	A pharmaceutical composition comprising hydroxychloroquine sulfate and preparation method thereof	December 18, 2041	Invention	PRC
6. . . .	The Company	A bifonazole solution and preparation process thereof	April 11, 2043	Invention	PRC
7. . . .	The Company	A sprayable metronidazole gel composition	August 18, 2034	Invention	PRC
8. . . .	The Company	A method for detecting related substances in a calcipotriol scalp solution	July 27, 2042	Invention	PRC
9. . . .	The Company	A soft ointment formulation comprising a tretinoin inclusion complex and clobetasol propionate, and preparation method thereof	August 26, 2033	Invention	PRC
10. . .	The Company	A selenium disulfide shampoo and a method for improving the stability of selenium disulfide shampoo	December 9, 2041	Invention	PRC
11. . .	The Company	A preparation process for a desonide cream	December 29, 2042	Invention	PRC
12. . .	The Company	Compound Clobetasol Propionate and Tretinoin Ointment	May 16, 2032	Invention	PRC
13. . .	The Company	Solid dispersion comprising clobetasol propionate and tretinoin, and preparation method thereof	January 29, 2033	Invention	PRC
14. . .	Zhiyan Biotechnology	An external cosmetic composition for acne treatment and skin repair and applications thereof	July 13, 2043	Invention	PRC

APPENDIX V STATUTORY AND GENERAL INFORMATION

No.	Owner	Patent name	Expiry date	Category	Place of registration
15. . .	Zhiyan Biotechnology	A facial cleansing mousse with acne-treating efficacy, and methods for its preparation and use	January 25, 2042	Invention	PRC
16. . .	Zhiyan Biotechnology	A composition and shampoo for preventing discoloration of selenium disulfide	November 24, 2042	Invention	PRC
17. . .	Chongqing Yaoyanyuan	A filtration device for preparing the extract of colquhounia root tablets	December 30, 2041	Invention	PRC
18. . .	Chongqing Yaoyanyuan	A medicinal material sorting device and its use method	July 25, 2042	Invention	PRC
19. . .	Chongqing Yaoyanyuan	A concentration device for extract of colquhounia root tablets and the concentration method thereof	August 4, 2042	Invention	PRC
20. . .	Chongqing Yaoyanyuan	A method for extracting the main active ingredient from colquhounia root and its application in preparing drugs for membranous nephropathy	March 22, 2043	Invention	PRC

Copyrights

As of the Latest Practicable Date, we had registered the following copyrights which we considered to be material to our business.

No.	Copyright name	Owner	Registration date	Place of registration
1. . .	Logo of Zhiyuan	The Company	May 24, 2023	PRC
2. . .	Packaging for Luofu® (洛芙®) New Series Products	The Company	October 30, 2023	PRC
3. . .	Metronidazole Gel	The Company	May 8, 2024	PRC
4. . .	Tranexamic Acid Tablets	The Company	May 16, 2024	PRC
5. . .	Clindamycin phosphate topical solution	The Company	January 24, 2025	PRC
6. . .	ZRVIVE Selenium Sulfide Anti-Dandruff Shampoo	Zhiyan Biotechnology	June 13, 2024	PRC
7. . .	ZRVIVE Whitening, Freckle-Lightening and Acne-Treating Essence Cream	Zhiyan Biotechnology	August 30, 2024	PRC
8. . .	ZRVIVE Selenium Sulfide Shampoo (Orange Selenium Bottle)	Zhiyan Biotechnology	September 4, 2025	PRC
9. . .	ZRVIVE	Zhiyan Biotechnology	December 4, 2025	PRC
10. . .	ZRVIVE Z + LOGO	Zhiyan Biotechnology	December 4, 2025	PRC

APPENDIX V

STATUTORY AND GENERAL INFORMATION

Domain Names

As of the Latest Practicable Date, we had registered the following internet domain names which we considered to be material to our business:

No.	Domain name	Owner	Registration date	Expiry date
1. . .	ziyondpharma.com	The Company	February 6, 2026	February 6, 2027
2. . .	zhirunskin.com	Zhiyan Biotechnology	July 12, 2022	July 12, 2027

C. FURTHER INFORMATION ABOUT OUR DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

1. Particulars of Directors’ Service Contracts

We [have] entered into a service contract with each of our Directors which contains provisions in relation to, among others, term of service and termination. The service contracts may be renewed in accordance with our Articles of Association and the applicable rules.

Save as disclosed in “Directors and Senior Management” and above, we have not entered into, and do not propose to enter into, any service contracts with any of our Directors in their respective capacities as Directors (excluding agreements expiring or determinable by any member of our Group within one year without payment of compensation other than statutory compensation).

2. Remuneration of Directors

For details of remunerations of Directors, see “Directors and Senior Management” and “Appendix I — Accountants’ Report — Notes to the Historical Financial Information — Note 8. Directors’ and Supervisors’ Emoluments” in this document.

Disclosure of Interests

Interests of our Directors and Chief Executive of the Company

Save as disclosed below, immediately following the completion of the [REDACTED] (assuming no exercise of the [REDACTED]) and the conversion of the Unlisted Shares into H Shares, so far as the Directors are aware, none of the Directors or chief executive of the Company will have any interest and/or short position (as applicable) in the Shares, underlying Shares or debentures of the Company or our associated corporation (within the meaning of Part XV of the SFO) which will be required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they are taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein, or which will be required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules to be notified to the Company and the Stock Exchange, once the H Shares are [REDACTED] on the Stock Exchange.

Name	Position	Nature of interest	Description of Shares	Number of Shares held	Approximate percentage of shareholding in the relevant class of Shares ⁽¹⁾	Approximate percentage of shareholding in the total share capital of the Company ⁽¹⁾
Mr. Xu	Chairman of the Board and executive Director	Beneficial owner; interests jointly held with other persons ⁽²⁾	Domestic Shares H Shares	[REDACTED] [REDACTED]	[REDACTED] [REDACTED]	[REDACTED] [REDACTED]

APPENDIX V

STATUTORY AND GENERAL INFORMATION

Name	Position	Nature of interest	Description of Shares	Number of Shares held	Approximate percentage of shareholding in the relevant class of Shares ⁽¹⁾	Approximate percentage of shareholding in the total share capital of the Company ⁽¹⁾
Mr. Xie	Executive Director, chief executive officer and general manager of the Company	Beneficial owner; interests jointly held with other persons ⁽²⁾	Domestic Shares H Shares	[REDACTED] [REDACTED]	[REDACTED] [REDACTED]	[REDACTED] [REDACTED]
Mr. Xu Dacheng (徐大成).	Non-executive Director and vice chairman of the Board	Interested in controlled corporation ⁽³⁾	Unlisted Shares H Shares	[REDACTED] [REDACTED]	[REDACTED] [REDACTED]	[REDACTED] [REDACTED]
Mr. You Bin (尤斌).	Executive Director and deputy general manager of the Company	Beneficial owner	Domestic Shares H Shares	[REDACTED] [REDACTED]	[REDACTED] [REDACTED]	[REDACTED] [REDACTED]
Dr. Cai Beilei (蔡蓓蕾).	Executive Director and deputy general manager of the Company	Beneficial owner	Domestic Shares H Shares	[REDACTED] [REDACTED]	[REDACTED] [REDACTED]	[REDACTED] [REDACTED]

Notes:

- (1) The calculation is based on the total number of [REDACTED] Domestic Shares and [REDACTED] H Shares in issue upon the [REDACTED] comprising (i) an aggregate of [REDACTED] H Shares to be converted from the Unlisted Shares and (ii) [REDACTED] H Shares to be issued pursuant to the [REDACTED] (without taking into account the H Shares which may be issued upon the exercise of the [REDACTED]).
- (2) Pursuant to the Acting-in-Concert Agreement, Mr. Xie agreed to act in concert with Mr. Xu by aligning their votes at the board meetings and shareholders’ meetings at the level of both Wuxi Zhonghe and our Company. As of the Latest Practicable Date, (i) Wuxi Zhonghe was the general partner of Wuxi Langming, Wuxi Langwei and Wuxi Langyi; and (ii) Mr. Xu was the general partner of Wuxi Langxing and Wuxi Zhiwen. As a result, each of Mr. Xu, Mr. Xie, Wuxi Zhonghe, Wuxi Langming, Wuxi Langwei, Wuxi Langyi, Wuxi Langxing and Wuxi Zhiwen is deemed to be interested in all the Shares in which each of them is interested under the SFO. For more details, see “Relationship with our Controlling Shareholders.”
- (3) Wuxi Boyi is a limited partnership managed by Mr. Xu Dacheng as its general partner. Harbour Avenue is owned as to 99.00% by Ms. Cai Huiyu, who is the spouse of Mr. Xu Dacheng. As a result, Mr. Xu Dacheng is deemed to be interested in an aggregate of 12,096,442 Shares held by Harbour Avenue and Wuxi Boyi under the SFO.

Interests of Substantial Shareholders

Save as disclosed in “Substantial Shareholders” in this document, the Directors are not aware of any other person (other than the Directors or chief executive of the Company) who will, immediately following the completion of the [REDACTED] (assuming no exercise of the [REDACTED]) and the conversion of the Unlisted Shares into H Shares, have an interest and/or short position in the Shares or underlying Shares which would fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of the Company or any other member of the Group.

3. Agency Fees or [REDACTED] Received

The [REDACTED] will receive an [REDACTED] in connection with the [REDACTED]. See “[REDACTED].” Save in connection with the [REDACTED], no [REDACTED], discounts, brokerages or other special terms have been granted by the Group to any person (including the Directors, promoters

APPENDIX V

STATUTORY AND GENERAL INFORMATION

and experts referred to in “— Other Information — Qualifications of Experts” below) in connection with the issue or sale of any capital or security of the Company or any member of the Group within the two years immediately preceding the date of this document.

Within the two years immediately preceding the date of this document, no [REDACTED] has been paid or is payable for [REDACTED], agreeing to [REDACTED], procuring [REDACTED] or agreeing to procure [REDACTED] for any share in or debentures of the Company.

4. Disclaimers

- (i) Save as disclosed in “History, Development and Corporate Structure,” none of our Directors nor any of the experts referred to under the paragraph headed “— Other Information — Qualifications of Experts” below has any direct or indirect interest in the promotion of our Company, or in any assets which have, within the two years immediately preceding the date of this document, been acquired or disposed of by or leased to any member of our Group, or are proposed to be acquired or disposed of by or leased to any member of our Group;
- (ii) Save in connection with the [REDACTED], none of our Directors is materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to the business of our Group taken as a whole;
- (iii) None of our Directors or their respective close associates or our Shareholders which to the knowledge of our Directors own more than 5% of our issued Shares (excluding treasury shares) has any interest in our five largest customers or suppliers during the Track Record Period; and
- (iv) Save as disclosed in “Directors and Senior Management,” none of our Directors is a director or employee of a company which has an interest or short position in the Shares or underlying Shares of our Company which would fall to be disclosed to our Company pursuant to Divisions 2 and 3 of Part XV of the SFO.

D. OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Company or our subsidiaries.

2. Litigation

As of the Latest Practicable Date, no member of our Group was involved in any litigation, arbitration, administrative proceedings or claims of material importance, and, so far as we are aware, no litigation, arbitration, administrative proceedings or claims of material importance were pending or threatened against any member of our Group.

3. Sole Sponsor

The Sole Sponsor has made an application on behalf of our Company to the Stock Exchange for the [REDACTED] of, and permission to [REDACTED], the H Shares to be [REDACTED] pursuant to the [REDACTED] and the H Shares to be converted from Unlisted Shares, on the Main Board of the Stock Exchange. The Sole Sponsor will receive an aggregate fee of US\$500,000 for acting as sole sponsor for the [REDACTED].

The Sole Sponsor satisfies the independence criteria applicable to sponsor set out in Rule 3A.07 of the Listing Rules.

APPENDIX V

STATUTORY AND GENERAL INFORMATION

4. Preliminary Expense

The Company did not incur any material preliminary expenses.

5. Promoters

The promoters of the Company are all then 17 shareholders of the Company as of November 27, 2020 before our conversion into a joint stock company with limited liability. Within the two years immediately preceding the date of this document, no cash, securities or other benefit has been paid, allotted or given nor are any proposed to be paid, allotted or given to any promoters in connection with the [REDACTED] or the related transactions described in this document.

6. Qualifications of Experts

The qualifications of the experts who have given opinions or advice in this document are as follows:

Name	Qualification
CITIC Securities (Hong Kong) Limited . .	A corporation licensed to carry on Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activities under the SFO
KPMG	Certified Public Accountants Public Interest Entity Auditor registered in accordance with the Accounting and Financial Reporting Council Ordinance
Zhong Lun Law Firm	Legal advisor to the Company as to PRC law
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.	Independent industry consultant
AVISTA Valuation Advisory Limited	Property valuer

7. Consents of Experts

Each of the experts named above [has given and has not withdrawn] its written consent to the issue of this document with the inclusion of its reports, letters or opinions (as the case may be) and the references to its name included herein in the form and context in which they are included.

As of the Latest Practicable Date, none of the experts named above had any shareholding in any member of our Group or right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

8. Stamp Duty

The sale, purchase and transfer of H Shares will be subject to Hong Kong stamp duty. The current rate charged on each of the seller and purchaser is 0.1% of the consideration or, if higher, the fair value of the H Shares being sold or transferred.

9. Binding Effect

This document shall have the effect, if any application is made pursuant hereto, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance as far as applicable.

APPENDIX V

STATUTORY AND GENERAL INFORMATION

10. Bilingual Document

The English language and Chinese language versions of this document are being published separately in reliance upon the exemption provided by section 4 of the Companies Ordinance (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

11. Miscellaneous

- (a) Save as otherwise disclosed “Financial Information,” “History, Development and Corporate Structure” and “[REDACTED],” within the two years immediately preceding the issue of this document:
 - (i) no share or debenture of any member of our Group has been issued or agreed to be issued or is proposed to be issued for cash or as fully or partly paid up otherwise than in cash;
 - (ii) no share or debenture of any member of our Group is under option or agreed conditionally or unconditionally to be put under option;
 - (iii) no [REDACTED], discounts, brokerages or other special terms have been granted in connection with the issue or sale of any capital of any member of our Group; and
 - (iv) no [REDACTED] has been paid or is payable for [REDACTED], agreeing to [REDACTED], procuring or agreeing to procure [REDACTED] for any shares in or debentures of our Company.
- (b) There are no founder or management or deferred shares in the Company.
- (c) There is no restriction affecting the remittance of profits or repatriation of capital of the Company into Hong Kong from outside Hong Kong.
- (d) There is no arrangement under which future dividends are waived or agreed to be waived.
- (e) There are no contracts for the hire or hire purchase of plant to or by our Group for a period of over one year which are substantial in relation to our Group’s business.
- (f) There have been no interruptions in our business which may have or have had a significant effect on our financial position in the last 12 months.
- (g) No part of the equity or debt securities of the Company is [REDACTED] or [REDACTED] in on any stock exchange, and no such [REDACTED] or permission to [REDACTED] on any stock exchange other than the Stock Exchange is being or is proposed to be sought.
- (h) the Company has no outstanding convertible debt securities or debentures.